The Scale of the Problem

Skeletal muscle mass declines approximately 3–8% per decade from the third and fourth decade, accelerating markedly after age 60. By the eighth decade, cumulative loss can reach 50% (Wilkinson et al., 2018). But the more immediate concern is strength: longitudinal studies show strength loss of 3–4% per year in men and 2.5–3% per year in women by age 75 — 2–5 times faster than mass loss (Mitchell et al., 2012).

This dissociation matters. Dynapenia — loss of strength and power — is a more consistent predictor of functional decline and mortality than muscle mass loss alone. You can appear to be maintaining muscle while losing the strength and power capacity that actually determines how well you move and function.

Three Mechanisms Driving This

Anabolic resistance is the hallmark of aging muscle. While basal muscle protein synthesis (MPS) rates are similar between young and old adults, the ability to upregulate MPS in response to protein feeding and exercise is significantly impaired with aging (Brook et al., 2016). A study comparing young (23 years) and older (69 years) men undergoing 6 weeks of identical resistance training found older adults showed blunted increases in muscle thickness (+3.5% vs +11% in young), cumulative MPS, ribosomal biogenesis, and translational efficiency. The mechanism involves impaired mTORC1 signaling, reduced ribosomal capacity, and impaired microvascular perfusion that limits amino acid delivery to muscle tissue.

Motor unit loss occurs preferentially in fast-twitch Type II fibers — the fibers responsible for power and strength. Denervation leads to compensatory reinnervation by slow motor neurons, producing a net shift toward a slower, weaker contractile profile. Motor unit loss precedes and likely drives sarcopenia rather than being a consequence of it (Sarto et al., 2024).

Satellite cell decline reduces the muscle's capacity for repair and regeneration. Satellite cells — the resident stem cells responsible for muscle maintenance — decrease with age, particularly in Type II fibers. However, the adaptive capacity is not lost: 12 weeks of progressive resistance training in older adults increased satellite cell content by ~40% in both fiber types and induced Type II fiber hypertrophy of +23.3% (Moro et al., 2020). The machinery is responsive — it just requires appropriate stimulus.

Three Evidence-Based Levers

Lever 1 Progressive resistance training. The 2026 ACSM Position Stand — synthesizing 137 systematic reviews and over 30,000 participants — confirms progressive resistance training as the primary intervention for muscle preservation in older adults, with the largest effect sizes at 70–79% 1RM (Currier et al., 2026). A 2026 meta-analysis of 72 RCTs confirms resistance training is superior to aerobic exercise for increasing skeletal muscle mass. The foundational principle is progressive overload: the stimulus must increase over time to continue driving adaptation. Frequency: ≥2 sessions per week, multiple sets per exercise for lower-body strength and hypertrophy.

Lever 2 Protein strategy. The RDA of 0.8g/kg/day is insufficient for adults over 40 who are training. Older adults require approximately 67% more protein than younger counterparts to produce the same MPS response (Murphy et al., 2023). Evidence-based targets: ≥1.6g/kg/day daily total (Morton et al.), distributed across 3–4 meals of 25–40g each, with ≥3g leucine per meal to activate mTORC1 signaling. A dose-response study in older men found that ≥30g per meal was required to significantly increase postexercise myofibrillar protein synthesis, with 45g producing the greatest amino acid incorporation (Holwerda et al., 2019). For plant-based athletes: pea protein matched whey for integrated MPS in older men — both 1.59%/day — while collagen protein did not (McKendry et al., 2024). A well-balanced vegan diet providing diverse protein sources does not compromise daily MPS rates in active older adults (Domić et al., 2025). Plant-based athletes should target ≥1.8–2.0g/kg/day to account for lower leucine density in plant protein sources.

Lever 3 Concurrent training structured correctly. A 2026 umbrella review of 17 meta-analyses (144 studies, 1,492 participants) confirms that concurrent training produces equivalent hypertrophy and maximal strength to resistance training alone, with significant additional cardiovascular benefit (Held et al., 2026). The interference effect on hypertrophy and maximal strength is minimal when sessions are structured correctly. The molecular basis: endurance exercise activates AMPK which suppresses mTORC1-S6K1 signaling; performing endurance exercise after resistance exercise downregulates prior RE-induced mTORC1 activity, while performing resistance exercise after endurance exercise preserves the subsequent protein synthesis response (Ogasawara et al., 2014). Practical rule: lift before running when combining in one session. Separate sessions by ≥3 hours when possible. Concurrent training outperforms either modality alone for reducing visceral fat while preserving lean mass — making it the optimal strategy for body recomposition in this population.

The Bottom Line

Muscle loss after 40 is real, begins earlier than most expect, and is driven by mechanisms that respond directly to evidence-based training and nutrition interventions. Progressive resistance training at adequate intensity, protein at ≥1.6g/kg/day distributed across meals, and concurrent training sequenced correctly — these are not advanced strategies. They are the evidence-based fundamentals for adults in this age group.

The adaptive capacity of muscle remains robust well into older age. A 2026 meta-analysis of 72 RCTs confirms that exercise — particularly resistance training — significantly improves skeletal muscle mass, strength, and physical performance even in adults with existing sarcopenia. The most important variable is sustained, progressive participation. Even minimal doses of resistance training produce substantial gains compared with inactivity.

Richard Skolasky is an ACE Certified Personal Trainer. This article is for general educational purposes only and does not constitute individualized exercise prescription. Consult a qualified healthcare provider before beginning or modifying a training program.

REFERENCES

Brook MS et al. (2016). Anabolic resistance to exercise in humans. J Physiology, 594(24), 7399–7417.

Churchward-Venne TA et al. (2014). Protein and exercise as countermeasures to offset sarcopenia. BioFactors, 40(2), 199–205.

Currier BS et al. (2026). ACSM Position Stand — resistance training prescription. Med Sci Sports Exerc, 58(4), 851–872.

Domić J et al. (2025). Vegan vs omnivorous diet, MPS in active older adults. J Nutrition, 155(4), 1141–1150.

Held S et al. (2026). Maximizing adaptations in concurrent training — umbrella review. Sports Medicine, 56(6), 1489–1512.

Holwerda AM et al. (2019). Dose-dependent increases in MPS during recovery from resistance exercise in older men. J Nutrition, 149(2), 221–230.

Lucio MCF et al. (2026). Exercise in older adults with sarcopenia — meta-analysis (72 RCTs). Scientific Reports.

McKendry J et al. (2024). Pea vs whey vs collagen protein in older males. Am J Clin Nutr, 120(1), 34–46.

Mitchell WK et al. (2012). Sarcopenia, dynapenia, and the impact of advancing age. Frontiers in Physiology, 3, 260.

Moro T et al. (2020). Resistance training promotes fiber type-specific myonuclear adaptations in older adults. J Applied Physiology, 128(4), 795–804.

Morton et al. Protein intake breakpoint for hypertrophy: 1.6g/kg/day. British Journal of Sports Medicine.

Murphy CH et al. (2023). Nutrition strategies to counteract sarcopenia. Proceedings of the Nutrition Society, 82(3), 419–431.

Ogasawara R et al. (2014). Order of concurrent endurance and resistance exercise modifies mTOR signaling. Am J Physiology, 306(10), E1155–62.

Sarto F et al. (2024). Neuromuscular impairment at different stages of sarcopenia. J Cachexia Sarcopenia Muscle, 15(5), 1797–1810.

Wilkinson DJ et al. (2018). The age-related loss of skeletal muscle mass and function. Ageing Research Reviews, 47, 123–132.